Levin Capital Strategies’s Aimmune Therapeutics AIMT Stock Holding History

Levin Capital Strategies’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-20,000	Closed	-$689K	–	358
2020 Q3	$689K	Buy	+20,000	New	+$426K	0.09%	113
2020 Q2	–	Sell	-10,000	Closed	-$144K	–	216
2020 Q1	$144K	Buy	+10,000	New	+$256K	0.02%	143

Levin Capital Strategies's AIMT Position: Q4 2020 in Review

Levin Capital Strategies sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 20,000 shares — an estimated $689K sold.

Levin Capital Strategies first reported a position in AIMT in Q1 2020 and held it in 2 quarters. The position peaked at $689K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Levin Capital Strategies reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Levin Capital Strategies sold 20,000 Aimmune Therapeutics shares in Q4 2020, an estimated $689K.
Levin Capital Strategies first reported a position in Aimmune Therapeutics in Q1 2020 and held it in 2 quarters.
Levin Capital Strategies's Aimmune Therapeutics position peaked at $689K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Levin Capital Strategies's 13F filing for Q4 2020, filed 16 Feb 2021.